November 10, 2010 – 5:23 pm
Biodesix announced that it has closed a $7.1M Series C round. The round was led by existing investors, who provided $5.1M of the total, and joined by five new investors. The proceeds of the the round will be used to fund commercialization activities for VeriStrat, a test designed to help guide treatment decisions [...]
November 3, 2010 – 12:07 pm
Many companies have reported awards from the Qualifying Therapeutic Discovery Project Program this week and several Colorado companies are included.
Inviragen (Fort Collins) received two grants totaling $488,958 for ongoing programs to develop vaccines against dengue and chikungunya viruses.
GlobeImmune (Louisville) has been awarded three grants totaling $733,438 for three development programs: GI-5005 the company’s lead product [...]
November 1, 2010 – 11:47 am
GlobeImmune Inc. announced additional data from a Phase 2b study of GI-5005 used in the treatment of patients with genotype 1 chronic hepatitis C virus (HCV). The addition of GI-5005 to standard of care improved sustained virologic response 12% compared to standard of care (SOC, , pegylated-interferon alpha 2a plus ribavirin) alone in patients [...]
October 9, 2010 – 2:38 pm
Inviragen and Pharmajet announced that they received a five-year $15.5M contract from National Institute of Allergy and Infectious Diseases, part of the NIH, to advance development of a needle free dengue vaccine. The development will focus on combining Inviragen’s DENVax with Pharmajet’s needle-free delivery system. The funding is earmarked for pre-clinical testing, regulatory [...]
October 1, 2010 – 2:10 pm
The second day of BioWest began with Chris Nolet of Ernst and Young discussing his company’s global biotechnology report. Nolet highlighted many of the figures, which can be found in the report that will be available for download here. Although biotechnology did not fare as badly in 2009 as anticipated in 2008 and [...]
October 1, 2010 – 9:17 am
The first day of CBSA’s BioWest included a wide variety of perspectives from presentations by emerging companies in Colorado to a panel focusing on international opportunities
The first presentation of the morning was offered by Thomas Warick, Director of the FDA’s Denver District. Warick discussed the challenges faced by the FDA when staffing and funding [...]
October 1, 2010 – 8:44 am
The first day of CBSA’s annual BioWest Conference brought the always-popular venture showcase in which the four finalists, selected from 21 entrants, presented their technologies to a panel of investors. Brief descriptions of the four finalists follow.
AmideBio, presented by CEO Misha Plam, has a process to manufacture peptides more efficiently and economically. The proprietary [...]
September 28, 2010 – 6:46 pm
The Colorado Institute for Drug, Device and Diagnostic Development (CID4) announced the two companies that received funding based on its initial solicitation. Sophono, Inc, based in Boulder, is receiving $600K to further the development of its Alpha 1 Magnetic Bone Anchored Hearing System. The system, which has received its CE mark signifying European [...]
September 15, 2010 – 1:32 pm
The Colorado Institute for Drug, Device and Diagnostic Development (CID4) has issued its second call for proposals from “Colorado life science technologies in need of funding and active management”. CID4, a private, not-for-profit entity launched in February, aims to help bridge the gap between research and commercialization for promising life science technologies [...]
August 30, 2010 – 1:38 pm
MBC Pharma announced that it received a $1,795,054 SBIR grant from the NIH. The two year grant will be used to expand the company’s pipeline of bone-targeted chemotherapeutics for the treatment of cancer induced bone disease. The grant money will be used to demonstrate if a new platform technology can produce effective compounds [...]
